Li N, Bu H, Liu J, Zhu J, et al. An open-label, multi-center, single-arm, phase 2 study of fluzoparib in patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian cancer. Clin Cancer Res 2021 Feb 8. pii: 1078-0432.CCR-20-3546.
PMID: 33558426